Cell therapy in end-stage liver disease: replace and remodel

Area of Science:

• Hepatology
• Regenerative Medicine
• Cellular Therapy

Background:

• End-stage liver disease (ESLD) has high mortality rates globally.
• Liver transplantation is effective but limited by donor organ scarcity.
• Cell therapy presents a viable alternative for ESLD treatment.

Purpose of the Study:

• To review cell therapy approaches for end-stage liver disease.
• To discuss various cell types used in transplantation for liver repair.
• To elucidate the mechanisms and challenges of cell therapy in liver disease.

Main Methods:

• Review of current literature on cell therapy for liver disease.
• Analysis of different cell types, including hepatocytes and stem cells.
• Examination of cell engraftment, proliferation, and functional restoration.

Main Results:

• Transplanted cells can replace host hepatocytes and restore liver function.
• Cellular therapies like mesenchymal stem cells can remodel the liver microenvironment.
• Cell therapy has progressed from animal models to early human clinical trials.

Conclusions:

• Cell therapy is a promising strategy for end-stage liver disease.
• Various cell types demonstrate potential for liver regeneration and repair.
• Addressing practical obstacles is crucial for advancing cell therapy in clinical practice.